City Therapeutics, an RNA interference (RNAi) startup founded by former Alnylam executives, completed a $99.5 million Series B financing to advance multiple RNAi candidates. The company said the funding will support the clinical development of its first three programs and expand its next-generation RNAi engineering platform. City’s positioning targets next-generation RNAi beyond liver-focused biology, reflecting investor demand for improved delivery and durability in tissues where RNAi has historically been harder to reach. The round underscores ongoing capital flow into RNAi modalities despite a wider biotech funding slowdown, particularly for companies that present a clear translational bridge from platform engineering to clinical activity. For the sector, City’s Series B also signals that “antibody-like” RNAi claims—when paired with a data-backed delivery strategy—remain attractive to institutional investors aiming for differentiated knockdown biology.